CLEVELAND, July 9, 2018 /PRNewswire/ -- ViewRay, Inc.
(Nasdaq: VRAY) announced today that Palos Health, in
partnership with Loyola Medicine, has installed ViewRay's MRIdian®
Linac System for MR image-guided radiation therapy at its Palos
Health South Campus in Orland Park,
Illinois. Palos Health becomes the first community hospital
in the United States, and the only
center in Illinois with the
company's next generation linear accelerator-based system.
MR image-guided radiotherapy represents the latest advance in
the field of radiation oncology. The anatomical detail only
available with MR soft tissue imaging enables daily on-table
treatment plan adaptation, allowing clinicians to quickly and
dynamically adjust for anatomical changes that may naturally occur
each day throughout the patient's course of treatment. The
technology also allows oncologists to visualize and actively track
the unique contours of the tumor and surrounding organs during
radiation delivery using a non-ionizing, streaming video
perspective unavailable until now. Combined, these capabilities
provide the Palos Health clinical team with the tools to
potentially improve tumor targeting precision and thus allow for
delivery of higher, and potentially more effective, radiation
doses.
"We are proud to be the first in our region to offer one of the
most exciting advances in cancer care – MR image-guided
radiotherapy. The ability to see, adapt and treat with
unprecedented clarity and improved accuracy will be of great
benefit to our patients in Chicagoland," said William Small Jr., M.D., FACRO,
FACR, FASTRO, professor and chair of the Department of
Radiation Oncology and director of the Cardinal Bernardin Cancer
Center at Loyola University.
"MRIdian presents new opportunities for real-time imaging and
motion management, allowing us to treat tumors that move with
respiration or other anatomical changes more precisely, and even
address many cancers that may previously have been difficult to
treat with radiation," said Raymond B.
Wynn, M.D., FACR, Professor, Vice Chairman of Clinical
Operations Department of Radiation Oncology Loyola University & Medical Director Radiation
Oncology at Loyola Center for Cancer Care and Research at Palos."
We look forward to sharing MRIdian's benefits with our patients
throughout Chicago."
The MRIdian Linac installation is the result of a partnership
between Loyola Medicine and Palos Health intended to bring renowned
oncology expertise, cutting-edge technology and coordinated,
collaborative patient care to patients in the suburbs of
Chicago.
"At Palos Health, we're committed to delivering the most
advanced cancer therapies to the patients we serve, so we're really
proud to be an early adopter of this important advance in cancer
care," said Terrence Moisan, M.D.,
chief executive officer of Palos Health. "It's exciting to be the
first community hospital to incorporate the MRIdian Linac system,
as we believe MR image-guided radiation therapy will become a
standard of care for all radiation oncology departments in the
future."
About ViewRay®
ViewRay, Inc. (Nasdaq: VRAY), designs, manufactures and markets
the MRIdian® radiation therapy system. MRIdian is built upon a
proprietary high-definition MR imaging system designed from the
ground up to address the unique challenges and clinical workflow
for advanced radiation oncology. Unlike MR systems used in
diagnostic radiology, MRIdian's high-definition MR was purpose
built to address specific challenges, including beam distortion,
skin toxicity, and other concerns that may potentially arise when
high magnetic fields interact with radiation beams. ViewRay and
MRIdian are registered trademarks of ViewRay, Inc.
This press release contains forward-looking statements.
Statements in this press release that are not purely historical are
forward-looking statements. These statements are subject to risks
and uncertainties that could cause future results to differ
materially from those referenced. Forward looking statements
include the advancement of science, and the ability of MRI-guided
radiation therapy programs to enable more treatment options,
improved tumor targeting precision and higher, more effective,
radiation dose. Given these uncertainties, the reader is
advised not to place any undue reliance on any forward-looking
statements. Additional risk factors include, among others, the
ability to raise the additional funding needed to continue to
pursue ViewRay's business and product development plans, the
inherent uncertainties associated with developing new products or
technologies, competition in the industry in which ViewRay operates
and overall market conditions. These forward-looking statements are
made as of the date of this press release, and ViewRay assumes no
obligation to update the forward-looking statements, or to update
the reasons why actual results differ from those projected in the
forward-looking statements, except as required by law. Investors
should consult all of the information set forth herein and should
also refer to the risk factor disclosure set forth in the reports
and other documents ViewRay files with the SEC available at
www.sec.gov.
View original
content:http://www.prnewswire.com/news-releases/loyola-medicinepalos-health-installs-viewrays-mridian-linac-system-for-mr-image-guided-radiation-therapy-300676773.html
SOURCE ViewRay, Inc.